Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

PHASE1,PHASE2

Phase

TERMINATED

Status

244

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

BIOLOGICAL: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
BIOLOGICAL: Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
BIOLOGICAL: Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
BIOLOGICAL: Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
BIOLOGICAL: Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
BIOLOGICAL: Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
BIOLOGICAL: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
BIOLOGICAL: Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose
BIOLOGICAL: Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose
DRUG: Ruxolitinib
BIOLOGICAL: Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose

MacroGenics